Literature DB >> 27130671

Universal influenza vaccines: a realistic option?

R D de Vries1, A F Altenburg1, G F Rimmelzwaan2.   

Abstract

The extensive antigenic drift displayed by seasonal influenza viruses and the risk of pandemics caused by newly emerging antigenically distinct influenza A viruses of novel subtypes has raised considerable interest in the development of so-called universal influenza vaccines. We review options for the development of universal flu vaccines and discuss progress that has been made recently.
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Keywords:  Antibodies; Immunity; Influenza; T lymphocytes; Universal vaccine; Virus vectors

Mesh：

Substances：

Year:  2016        PMID： 27130671     DOI： 10.1016/j.cmi.2015.12.005

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  9 in total

1.  Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone.

Authors:  Peter Pushko; Irina Tretyakova; Rachmat Hidajat; Xiangjie Sun; Jessica A Belser; Terrence M Tumpey
Journal:  Vaccine       Date:  2018-06-07       Impact factor: 3.641

Review 2.  Factors affecting immune responses to the influenza vaccine.

Authors:  Maria R Castrucci
Journal:  Hum Vaccin Immunother       Date:  2017-07-21       Impact factor: 3.452

3.  Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.

Authors:  A F Altenburg; S E Magnusson; F Bosman; L Stertman; R D de Vries; G F Rimmelzwaan
Journal:  Clin Exp Immunol       Date:  2017-07-24       Impact factor: 4.330

4.  One Step Forward in the Road Toward a Universal Influenza Vaccine.

Authors:  Octavio Ramilo; Rosa Rodriguez-Fernandez; Asuncion Mejias
Journal:  J Infect Dis       Date:  2017-12-27       Impact factor: 5.226

5.  Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity.

Authors:  Rory D de Vries; Nella J Nieuwkoop; Fiona R M van der Klis; Marion P G Koopmans; Florian Krammer; Guus F Rimmelzwaan
Journal:  J Infect Dis       Date:  2017-12-27       Impact factor: 5.226

Review 6.  Improving the selection and development of influenza vaccine viruses - Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015.

Authors:  Alan Hampson; Ian Barr; Nancy Cox; Ruben O Donis; Hirve Siddhivinayak; Daniel Jernigan; Jacqueline Katz; John McCauley; Fernando Motta; Takato Odagiri; John S Tam; Anthony Waddell; Richard Webby; Thedi Ziegler; Wenqing Zhang
Journal:  Vaccine       Date:  2017-01-25       Impact factor: 3.641

7.  High throughput discovery of influenza virus neutralizing antibodies from phage-displayed synthetic antibody libraries.

Authors:  Ing-Chien Chen; Yi-Kai Chiu; Chung-Ming Yu; Cheng-Chung Lee; Chao-Ping Tung; Yueh-Liang Tsou; Yi-Jen Huang; Chia-Lung Lin; Hong-Sen Chen; Andrew H-J Wang; An-Suei Yang
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

Review 8.  Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications.

Authors:  Erin Sparrow; Martin Friede; Mohamud Sheikh; Siranda Torvaldsen; Anthony T Newall
Journal:  Vaccine       Date:  2016-09-09       Impact factor: 3.641

9.  Development and evaluation of a rapid nucleic acid amplification method to detect influenza A and B viruses in human respiratory specimens.

Authors:  Sonja Elf; Pauliina Auvinen; Lisa Jahn; Karoliina Liikonen; Solveig Sjöblom; Päivi Saavalainen; Minna Mäki; Kevin E Eboigbodin
Journal:  Diagn Microbiol Infect Dis       Date:  2018-04-18       Impact factor: 2.803
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.